Spago Nanomedical AB — Investor Relations & Filings

Spago Nanomedical AB is a clinical-stage company specializing in nanomedicine for the diagnosis and treatment of cancer. The company's development is centered on a proprietary platform of polymeric nanomaterials designed to accumulate in tumor tissue, enabling targeted medical applications. Its portfolio includes two primary projects. The first, SpagoPix (SN132D), is a gadolinium-free contrast agent for magnetic resonance imaging (MRI) aimed at improving the visualization of solid tumors. The second project, Tumorad (177Lu-SN201), is a radionuclide therapy that utilizes the same nanomaterial platform to deliver a therapeutic radioisotope directly to cancer cells, offering a targeted treatment approach intended to minimize damage to healthy tissue.